Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
11
×
clinical trials
fda
11
×
life sciences
national blog main
boston blog main
boston top stories
deals
boston
eli lilly
national top stories
san francisco blog main
amgen
investing
new york blog main
san diego blog main
san diego top stories
alexion pharmaceuticals
alnylam pharmaceuticals
blueprint medicines
calcitonin gene-related peptide
chronic migraine
detroit blog main
detroit top stories
drugs
episodic migraine
indiana blog main
indiana top stories
new enterprise associates
new york top stories
novartis
rare disease drugs
rna interference
roche
san francisco top stories
teva pharmaceutical
the medicines company
achaogen
adams street partners
akouos
What
drug
11
×
medicines
11
×
fda
therapeutics
new
approval
approved
company
disease
ipo
brings
cancer
candidate
cholesterol
class
deal
developed
developing
lead
migraine
muscle
nod
pain
pharma
pharmaceuticals
ready
regulatory
research
roche
starts
team
wins
won
acquire
affects
agreed
alternative
americans
amgen
announced
Language
unset
Current search:
fda
×
biotech
×
medicines
×
drug
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines